Drugs / CEP-37250/KHK2804
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01447732 | Oct 2011 → Jan 2015 | colorectal adenocarcinoma, pancreatic adenocarcinoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEP-37250/KHK2804 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01447732 ↗ |
| Modality | Monoclonal antibody | “CEP-37250/KHK2804 is a recombinant, humanized, non-fucosylated, monoclonal antibody” PMID 27457707 ↗ Dec 2016 |
| Route | Intravenous | “patients (n = 31) with solid tumors received increasing doses of CEP-37250/KHK2804 (0.03-1.0 mg/kg) intravenously once weekly” PMID 27457707 ↗ Dec 2016 |